Product Description
BIIB107 is a humanized monoclonal antibody that targets alpha4 integrins, which are essential for leukocyte trafficking into the brain and are an important element in pathology of MS. It’s hypothesized that BIIB107, by disrupting the interaction of alpha4 integrin and its ligands and therefore preventing leukocyte trafficking into the brain, has the potential to reduce inflammation and provide therapeutic benefit in MS. (Sourced from: https://www.biogen.com/science-and-innovation/pipeline.html)
Mechanisms of Action: ITGA4 Inhibitor
Novel Mechanism: No
Modality: Antibody
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Biogen
Company Location: CAMBRIDGE MA 02142
Company CEO: Michel Vounatsos
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Multiple Sclerosis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 271HV101 | P1 |
Completed |
Multiple Sclerosis |
2024-03-05 |
43% |